|
- The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure
- The standalone booth features STAgora simulation and an interactive touchscreen experience
- An enhanced CURECA model is presented, illustrating next-generation automated laboratory workflows
- Strong on-site engagement from global healthcare and laboratory professionals, researchers, and industry stakeholders
SEOUL, South Korea, April 20, 2026 /PRNewswire/ -- Seegene, a global molecular diagnostics company, announced that it introduced STAgora™, a real-time data analytics platform based on aggregated statistical testing data, and presented an enhanced model of its automated PCR workflow concept CURECA™ at ESCMID Global 2026 (formerly ECCMID), held April 17–21 in Munich, Germany, drawing interest from healthcare professionals attending the event.
Throughout the exhibition, Seegene's booth drew strong on-site interest from healthcare professionals, laboratory specialists, academic researchers, and industry stakeholders worldwide. Visitors explored the automated PCR workflow at the CURECA station and engaged in discussions about its potential applications. At the STAgora station, attendees experienced live simulations of the platform, demonstrating strong interest in its intuitive interface and aggregated data visualization capabilities.
At the conference, Seegene presented its key message, "From Numbers to Insights", highlighting how automated testing infrastructure and real-time data analytics can work together to support a better understanding of population-level and public health-related trends.
"STAgora is designed to connect PCR testing data generated around the world in real time and provide a clearer view of infectious disease trends based on aggregated statistics," said Young Seag Baeg, New Business Officer at Seegene. "We are continuing to explore how real-time data analytics, combined with automated testing infrastructure, can help laboratories better understand infection patterns and expand the practical use of aggregated testing data."
At the booth, visitors explored real-time dashboards presenting comparative data between single-target and syndromic PCR testing outputs, regional infection trends over time, pathogen-specific positivity rates and co-infection patterns. The ability to analyze aggregated test results alongside regional epidemiological data drew particular attention from attendees.
Seegene also showcased an enhanced model of CURECA. Visitors examined the system's modular structure and automation workflow, which integrates preprocessing, nucleic acid extraction, amplification, and result processing. Many attendees engaged in in-depth discussions about the system's architecture and its applicability in real laboratory environments.
A clinician from a university hospital in Germany who experienced the STAgora demonstration commented that the platform provided a more intuitive way to explore and visualize aggregated testing data trends. The clinician noted that the ability to view regional infection trends alongside aggregated test results in real time was particularly impactful.
"Interest in STAgora's real-time data capabilities and practical applications was strong throughout the event," said Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene. "We plan to expand pilot programs and collaborative evaluations with healthcare and laboratory institutions to further evaluate the platform and support its potential future adoption."
This approach was also noted to align with syndromic PCR testing, which enables the simultaneous detection of multiple pathogens, supporting broader analysis of aggregated infection patterns across different settings.
Seegene previously introduced STAgora and CURECA to the global diagnostics community at major international conferences including ADLM and ESCMID Global 2025. At ESCMID 2026, the company featured an expanded standalone booth where visitors engaged with STAgora through an interactive touchscreen demonstration zone. An enhanced model of CURECA was also displayed, illustrating the company's vision for future workflow automation.
During the conference, Seegene held discussions with global partners and leading laboratories on the adoption and validation of STAgora and CURECA. The company also hosted dedicated sessions for healthcare and laboratory professionals, particularly in Europe, to present use cases and potential applications of its technologies.
Seegene stated that it plans to further expand collaboration with clinical, academic, and research partners to support the implementation and validation of its data-driven diagnostics platform, with the goal of accelerating real-world adoption across global healthcare settings.
About Seegene
Seegene is a global molecular diagnostics company with more than 25 years of expertise in research, development and manufacturing of syndromic real-time PCR technologies. The company is widely recognized for its proprietary multiplex PCR technology, which enables the simultaneous detection of multiple pathogens in a single test.
A core feature of Seegene's syndromic real-time PCR technology is its ability to detect up to 14 pathogens that cause similar signs and symptoms in a single tube while providing quantitative information to support more efficient clinical decision-making.
Seegene's technological capabilities were demonstrated during the COVID-19 pandemic, when the company supplied more than 340 million COVID-19 tests to over 100 countries worldwide.
Building on its molecular diagnostics expertise, Seegene is expanding beyond assay-based diagnostics to develop an integrated diagnostic ecosystem. The company is advancing new technologies including STAgora™, a real-time diagnostic data analytics platform, and CURECA™, a fully automated PCR system designed to streamline the entire molecular testing workflow.
Through its Technology Sharing Initiative and global partnerships, Seegene aims to broaden access to molecular diagnostics technologies and strengthen global preparedness for infectious diseases.
- The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure
- The standalone booth features STAgora simulation and an interactive touchscreen experience
- An enhanced CURECA model is presented, illustrating next-generation automated laboratory workflows
- Strong on-site engagement from global healthcare and laboratory professionals, researchers, and industry stakeholders
SEOUL, South Korea, April 20, 2026 /PRNewswire/ -- Seegene, a global molecular diagnostics company, announced that it introduced STAgora™, a real-time data analytics platform based on aggregated statistical testing data, and presented an enhanced model of its automated PCR workflow concept CURECA™ at ESCMID Global 2026 (formerly ECCMID), held April 17–21 in Munich, Germany, drawing interest from healthcare professionals attending the event.
Throughout the exhibition, Seegene's booth drew strong on-site interest from healthcare professionals, laboratory specialists, academic researchers, and industry stakeholders worldwide. Visitors explored the automated PCR workflow at the CURECA station and engaged in discussions about its potential applications. At the STAgora station, attendees experienced live simulations of the platform, demonstrating strong interest in its intuitive interface and aggregated data visualization capabilities.
At the conference, Seegene presented its key message, "From Numbers to Insights", highlighting how automated testing infrastructure and real-time data analytics can work together to support a better understanding of population-level and public health-related trends.
"STAgora is designed to connect PCR testing data generated around the world in real time and provide a clearer view of infectious disease trends based on aggregated statistics," said Young Seag Baeg, New Business Officer at Seegene. "We are continuing to explore how real-time data analytics, combined with automated testing infrastructure, can help laboratories better understand infection patterns and expand the practical use of aggregated testing data."
At the booth, visitors explored real-time dashboards presenting comparative data between single-target and syndromic PCR testing outputs, regional infection trends over time, pathogen-specific positivity rates and co-infection patterns. The ability to analyze aggregated test results alongside regional epidemiological data drew particular attention from attendees.
Seegene also showcased an enhanced model of CURECA. Visitors examined the system's modular structure and automation workflow, which integrates preprocessing, nucleic acid extraction, amplification, and result processing. Many attendees engaged in in-depth discussions about the system's architecture and its applicability in real laboratory environments.
A clinician from a university hospital in Germany who experienced the STAgora demonstration commented that the platform provided a more intuitive way to explore and visualize aggregated testing data trends. The clinician noted that the ability to view regional infection trends alongside aggregated test results in real time was particularly impactful.
"Interest in STAgora's real-time data capabilities and practical applications was strong throughout the event," said Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene. "We plan to expand pilot programs and collaborative evaluations with healthcare and laboratory institutions to further evaluate the platform and support its potential future adoption."
This approach was also noted to align with syndromic PCR testing, which enables the simultaneous detection of multiple pathogens, supporting broader analysis of aggregated infection patterns across different settings.
Seegene previously introduced STAgora and CURECA to the global diagnostics community at major international conferences including ADLM and ESCMID Global 2025. At ESCMID 2026, the company featured an expanded standalone booth where visitors engaged with STAgora through an interactive touchscreen demonstration zone. An enhanced model of CURECA was also displayed, illustrating the company's vision for future workflow automation.
During the conference, Seegene held discussions with global partners and leading laboratories on the adoption and validation of STAgora and CURECA. The company also hosted dedicated sessions for healthcare and laboratory professionals, particularly in Europe, to present use cases and potential applications of its technologies.
Seegene stated that it plans to further expand collaboration with clinical, academic, and research partners to support the implementation and validation of its data-driven diagnostics platform, with the goal of accelerating real-world adoption across global healthcare settings.
About Seegene
Seegene is a global molecular diagnostics company with more than 25 years of expertise in research, development and manufacturing of syndromic real-time PCR technologies. The company is widely recognized for its proprietary multiplex PCR technology, which enables the simultaneous detection of multiple pathogens in a single test.
A core feature of Seegene's syndromic real-time PCR technology is its ability to detect up to 14 pathogens that cause similar signs and symptoms in a single tube while providing quantitative information to support more efficient clinical decision-making.
Seegene's technological capabilities were demonstrated during the COVID-19 pandemic, when the company supplied more than 340 million COVID-19 tests to over 100 countries worldwide.
Building on its molecular diagnostics expertise, Seegene is expanding beyond assay-based diagnostics to develop an integrated diagnostic ecosystem. The company is advancing new technologies including STAgora™, a real-time diagnostic data analytics platform, and CURECA™, a fully automated PCR system designed to streamline the entire molecular testing workflow.
Through its Technology Sharing Initiative and global partnerships, Seegene aims to broaden access to molecular diagnostics technologies and strengthen global preparedness for infectious diseases.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows
Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows
In the news release, "One Cell Beats Six! Amflow's Flagship, Powered by Ampace, Breaks the 700Wh Bottleneck", issued on April 17, 2026 by Ampace over PR Newswire, we are advised by the company that the sentence, should read "... collaboration between Avinox and Ampace sets a new benchmark..." rather than "...collaboration between Amflow and Ampace sets a new benchmark..." as originally issued inadvertently. Complete, corrected release follows:
SHENZHEN, China, April 17, 2026 /PRNewswire/ -- Amflow, a high-end e-bike brand, officially launched its new super flagship PX series. The brand's high-end models, Amflow PX Carbon and PX Carbon Pro, exclusively adopt the Ampace 50480 cylindrical lithium battery — the new cylindrical 700Wh battery which weighs just 3.18 kg, giving an impressive energy density of 220Wh/kg. This design shatters long-standing technical limits and delivers a jaw-dropping performance leap: one cell outperforms six standard 21700 cells.
Built for full-scenario, high-performance riding, the Amflow PX series keeps things ultra-light with a 2.4kg frame and a total bike weight of just 20.6kg, making it incredibly nimble whether you're hitting the trails or grinding out long-distance rides. To adapt to this performance base and unleash the full potential of the model. Co-developed by Amflow and Ampace, the 50480 battery ditches the old 6-cell parallel setups and introduces a game-changing 10-cell custom cylindrical architecture, redefining what high-end e-bike power can do.
Boasting 700Wh capacity, the battery has multiple advantages: three times fast charging with 40 percent higher charging rate for quick recharging; 70 percent lower internal resistance for energy saving; and industry-first 400 long cycles at 45℃, balancing endurance and durability to eliminate outdoor range anxiety.
This deep collaboration between Avinox and Ampace sets a new benchmark for e-bike battery performance. It also marks Ampace's official entry into the high-end e-bike space, strengthening its lead in the electric two-wheeler market and locking in its position as a go-to leader in full-scenario, high-end lithium battery solutions.
Ampace Official Website: https://en.ampace.com/
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
One Cell Beats Six! Amflow's Flagship, Powered by Ampace, Breaks the 700Wh Bottleneck
